Hagen Amalie Nilsen, Ariansen Inger, Hanssen Tove Aminda, Lappegård Knut Tore, Eggen Anne Elise, Løchen Maja-Lisa, Njølstad Inger, Wilsgaard Tom, Hopstock Laila Arnesdatter
Department of Medicine, Nordland Hospital, Parkveien 96, Nordland, 8005 Bodø, Norway.
Department of Chronic Diseases and Ageing, Norwegian Institute of Public Health, Folkehelseinstituttet, Postboks 222 Skøyen, 0213 Oslo, Norway.
Eur Heart J Open. 2022 Sep 22;2(5):oeac061. doi: 10.1093/ehjopen/oeac061. eCollection 2022 Sep.
To study change over 8 years in cardiovascular risk, achievement of national guideline-based treatment targets of lipids, blood pressure (BP) and smoking in primary prevention of cardiovascular disease (CVD), medication use, and characteristics associated with target achievement among individuals with high CVD risk in a general population.
We followed 2524 women and men aged 40-79 years with high risk of CVD attending the population-based Tromsø study in 2007-08 (Tromsø6) to their participation in the next survey in 2015-16 (Tromsø7). We used descriptive statistics and regression models to study change in CVD risk and medication use, and characteristics associated with treatment target achievement. In total, 71.4% reported use of BP- and/or lipid-lowering medication at second screening. Overall, CVD risk decreased during follow-up, with a larger decrease among medication users compared with non-users. Treatment target achievement was 31.0% for total cholesterol <5 mmol/L, 27.3% for LDL cholesterol <3 mmol/L, 43.4% for BP <140/90 (<135/85 if diabetes) mmHg, and 85.4% for non-smoking. A total of 9.8% reached all treatment targets combined. Baseline risk factor levels and current medication use had the strongest associations with treatment target achievement.
We found an overall improvement in CVD risk factors among high-risk individuals over 8 years. However, guideline-based treatment target achievement was relatively low for all risk factors except smoking. Medication use was the strongest characteristic associated with achieving treatment targets. This study has demonstrated that primary prevention of CVD continues to remain a major challenge.
研究8年间心血管疾病风险的变化、在心血管疾病(CVD)一级预防中基于国家指南的血脂、血压(BP)和吸烟治疗目标的达成情况、药物使用情况,以及普通人群中高CVD风险个体实现治疗目标的相关特征。
我们对2007 - 2008年参加基于人群的特罗姆瑟研究(特罗姆瑟6)的2524名40 - 79岁CVD高风险的男性和女性进行随访,直至他们参与2015 - 2016年的下一次调查(特罗姆瑟7)。我们使用描述性统计和回归模型来研究CVD风险和药物使用的变化,以及与治疗目标达成相关的特征。在第二次筛查时,共有71.4%的人报告使用了降压和/或降脂药物。总体而言,随访期间CVD风险降低,与未使用者相比,药物使用者的风险降低幅度更大。总胆固醇<5 mmol/L的治疗目标达成率为31.0%,低密度脂蛋白胆固醇<3 mmol/L的达成率为27.3%,血压<140/90(糖尿病患者为<135/85)mmHg的达成率为43.4%,戒烟的达成率为85.4%。共有9.8%的人综合达到了所有治疗目标。基线风险因素水平和当前药物使用与治疗目标达成的关联最强。
我们发现高危个体在8年间心血管疾病风险因素总体有所改善。然而,除吸烟外,所有风险因素基于指南的治疗目标达成率相对较低。药物使用是与实现治疗目标相关的最强特征。这项研究表明,心血管疾病的一级预防仍然是一项重大挑战。